TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and… Read More..

Partnership aims to include Aclarion's surgical decision support technology within ATEC's AlphaInformatiX platform to better inform spine surgery Aclarion's Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO - (NewMediaWire) -… Read More..

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such… Read More..